Aastrom Moves Cell Therapy To The Verge Of Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Aastrom Biosciences Inc. is on the verge of entering Phase III with its first biologic, the cell therapy ixmyelocel-T, now that the Michigan biotech has finally nailed down the specifics of a Special Protocol Assessment with FDA.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.